ICL ICL Group Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of A pril , 201 7

Commission File Number: 001-13742

ISRAEL CHEMICALS LTD.

(Exact name of registrant as specified in its charter)

Israel Chemicals Ltd.

Millennium Tower

23 Aranha Street

P.O. Box 20245

Tel Aviv, 61202 Israel

(972-3) 684-4400

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form   20-F or Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation   S-T   Rule   101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation   S-T   Rule   101(b)(7):

ISRAEL CHEMICALS LTD.

  INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form S-8 (Registration Number: 333-205518) of Israel Chemicals Ltd. and to be a part thereof from the date on which this report is filed, to the exte nt not superseded by documents or reports subsequently filed or furnished.

ISRAEL CHEMICALS LTD.

Item 1

ICL's response to publication in the media regarding the sale of ICL's share in IDE

Further to Item 5B. 'Operating and Financial Review and Prospects – Liquidity and Capital Resources' of the Company's 2016 Annual Report (20F), regarding the examination to divest ICL's share in IDE Technologies Ltd. (" IDE "), and further to the publication in the Israeli media, the Company confirms that the Company is holding negotiations for the sale of ICL's share in IDE (50%).

There is no assurance that these negotiations will materialize to an engagement in a transaction and/or as to the terms and conditions of such transaction. The Company will report If such transaction materializes into an engagement.